Journal
ADVANCES IN THERAPY
Volume -, Issue -, Pages -Publisher
SPRINGER
DOI: 10.1007/s12325-022-02362-4
Keywords
Early drug development; Enrichment design; New trial design; Precision medicine; Tissue-agnostic drug
Funding
- Roche Farmaceutica Quimica Lda
Ask authors/readers for more resources
Cancer diagnosis and therapeutics have traditionally relied on organ-based pathological classification, but with the advancement of precision medicine, targeted therapies based on specific genomic or molecular alterations have emerged. Cancer is now recognized as a heterogeneous disease with multiple targetable mutations, leading to the development of novel trial designs and histology-agnostic targeted therapeutic agents.
Cancer diagnosis and therapeutics have been traditionally based on pathologic classification at the organ of origin. The availability of an unprecedented amount of clinical and biologic data provides a unique window of opportunity for the development of new drugs. What was once treated as a homogeneous disease with a one-size-fits-all approach was shown to be a rather heterogeneous condition, with multiple targetable mutations that can vary during the course of the disease. Clinical trial designs have had to adapt to the exponential growth of targetable mechanisms and new agents, with ensuing challenges that are closer to those experienced with rare diseases and orphan medicines. To face these problems, precision/enrichment and other novel trial designs have been developed, and the concept of histology-agnostic targeted therapeutic agents has emerged. Patients are selected for a specific agent based on specific genomic or molecular alterations, with the same compound used to potentially treat a multiplicity of cancers, granted that the actionable driver alteration is present. There are currently approved drugs for such indications, but this approach has raised issues on multiple levels. This review aims to address the challenges of this new concept and provide insights into possible solutions and frameworks on how to tackle them.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available